Nurse-led titration models of care for heart failure reduced ejection fraction: a systematic narrative review of characteristics, patient outcomes, and healthcare resource utilization.

Eur J Cardiovasc NursSep 8, 2026
Clinical ResearchCardiology

Amanda Pereira-Salgado, Sabine Kleissl-Muir, Ella Zomer et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic narrative review examined nurse-led titration (NLT) models of care for patients with heart failure with reduced ejection fraction (HFrEF). Sixteen studies were analyzed, revealing that NLT is associated with favorable mortality outcomes and potential reductions in rehospitalizations linked to increased nurse visits and medication use. The review underscores the effectiveness of NLT in managing HFrEF.

Key findings

  • Favorable mortality outcomes were observed in patients receiving nurse-led titration care.
  • Increased heart failure nurse visits correlated with reduced rehospitalizations.
  • Greater heart failure medication use was associated with improved patient outcomes.

Why it matters

Understanding the characteristics and outcomes of nurse-led titration models can help clinicians optimize care for patients with HFrEF, potentially improving patient survival and reducing hospital readmissions.

Source

PubMed · PMID 41871452

Published in Eur J Cardiovasc Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.